AbbVie has increased its dividend by 333% since 2013. The company has raised its dividend for 54 consecutive years, a streak that includes its time as part of Abbott Labs. This qualifies it as a Dividend King, a group requiring at least 50 years of consecutive dividend increases.
Its forward dividend yield currently stands above 3.1%. The company faced a patent cliff with its drug Humira, which began facing biosimilar competition in the U.S. in late 2023. Despite declining Humira sales, AbbVie now reports robust sales growth, having diversified its product lineup through internal research and acquisitions.
Coca-Cola has increased its dividend for 63 consecutive years. In February 2025, its board approved a 5.2% dividend increase. Over the past decade, the company's dividend has grown by approximately 46%, with a current yield of 2.7%.
The company, founded in 1886, now has 30 brands generating at least $1 billion in annual sales. It holds a market share of 14% in developed markets and 7% in developing and emerging markets.
Johnson & Johnson has also increased its dividend for 63 consecutive years. Over the past decade, its dividend payout has risen by more than 73%. A strong stock performance in the second half of 2025 has resulted in a current dividend yield of 2.4%.
Founded in 1886, the company spun off its consumer health unit, Kenvue, in 2023. It is now focused on pharmaceuticals and medical technology, with 103 programs in clinical development. More than half of these programs are in late-stage testing or awaiting regulatory approvals.
The Motley Fool Stock Advisor analyst team recently identified 10 stocks as the best for investors to buy now. AbbVie was not on that list. The team noted that its Stock Advisor service has a total average return of 955%, compared to 196% for the S&P 500.